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AbsTrACT
Aims The histopathological diagnosis of low- grade 
dysplasia (LGD) in Barrett’s oesophagus (BO) is 
associated with poor interobserver agreement and 
guidelines dictate expert review. To facilitate nationwide 
expert review in the Netherlands, a web- based digital 
review panel has been set up, which currently consists 
of eight ’core’ pathologists. The aim of this study was to 
evaluate if other pathologists from the Dutch BO expert 
centres qualify for the expert panel by assessing their 
performance in 80 consecutive LGD reviews submitted to 
the panel.
Methods Pathologists independently assessed digital 
slides in two phases. Both phases consisted of 40 cases, 
with a group discussion after phase I. For all cases, 
a previous consensus diagnosis made by five core 
pathologists was available, which was used as reference. 
The following criteria were used: (1) percentage of 
’indefinite for dysplasia’ diagnoses, (2) percentage 
agreement with consensus diagnosis and (3) proportion 
of cases with a consensus diagnosis of dysplasia 
underdiagnosed as non- dysplastic. Benchmarks were 
based on scores of the core pathologists.
results After phase I, 1/7 pathologists met the 
benchmark score for all quality criteria, yet three 
pathologists only marginally failed the agreement with 
consensus diagnosis (score 68.3%, benchmark 69%). 
After a group discussion and phase II, 5/6 remaining 
aspirant panel members qualified with all scores within 
the benchmark range.
Conclusions The Dutch BO review panel now 
consists of 14 pathologists, who—after structured 
assessments and group discussions—can be considered 
homogeneous in their review of biopsies with LGD.
InTrOduCTIOn
Low- grade dysplasia (LGD) is an important histo-
logical risk factor for progression to oesophageal 
adenocarcinoma in patients with Barrett’s oesoph-
agus (BO). The histological diagnosis of LGD is 
however challenging, because early morphological 
changes of dysplasia are difficult to distinguish from 
reactive atypia of reflux- induced inflammation. As 
a result, the interobserver agreement for the diag-
nosis of LGD is poor, and LGD is widely overdiag-
nosed in community practice. Two studies from our 
group have shown that 73%–85% of the commu-
nity LGD cases are downstaged to non- dysplastic 
BO (NDBO) by BO expert pathologists and that 
these downstaged cases have a low progression 
risk during follow- up. However, if the diagnosis 
LGD is confirmed by an expert BO pathologist, 
the risk of neoplastic progression is approximately 
10% per patient- year.1 2 This risk increases signifi-
cantly if multiple expert pathologists agree on this 
diagnosis.3
New guidelines dictate review of all dysplastic 
BO cases by an expert pathologist,4–7 but the 
concept of ‘expert pathologist’ is ill- defined, and 
access to expert review is not widely available. 
To facilitate expert review in the Netherlands, a 
national, web- based digital histology review plat-
form has been set- up by the eight BO expert centres 
in the Netherlands. All diagnostic work- up and 
treatment of early BO neoplasia is centralised in 
these eight centres. The histology review panel was 
built around five ‘core pathologists’. These ‘core’ 
BO expert pathologists had a track record in the 
field of BO of >10 years (range 10–30 years), had 
participated in multiple teaching programmes (ie, 
www. best- academia. eu) and had each coauthored 
on >10 peer reviewed publications in this field.8–12
In a prior study, we evaluated if we could expand 
the number of pathologists in the panel to reduce 
the individual workload, reduce lead time and 
obtain nationwide coverage while maintaining the 
assessment quality and homogeneity.12 For this, 10 
other gastrointestinal (GI) pathologists from the 
eight BO expert centres assessed digitalised slides of 
60 endoscopy procedures, enriched for dysplasia. 
This case set had also been assessed by the five core 
pathologists. Three of the 10 pathologists met the 
stringent benchmark quality criteria for the case set, 
as established based on the results of the five core 
pathologists. Therefore, these three pathologists 
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Table 1 Patient and endoscopy characteristics
Cases phase I 
(n=41)
Cases phase II 
(n=39)
Age at endoscopy in years (median, IQR) 67 (61–72) 66 (59–70)
Sex (male) (n, %) 26 (68) 31 (80%)
Levels biopsied (median, IQR) 2 (1–4) 2 (1–3)
Total biopsies (median, IQR) 8 (4–12) 7 (3–11)
Initial community diagnosis, n (%)
  IND 16 (39) 16 (41)
  LGD 25 (61) 23 (59)
IND, indefinite for dysplasia; IQR, interquartile range; LGD, low- grade dysplasia.
were considered to be homogeneous in their histological assess-
ment with the five core pathologists and joined the core group 
of the expert panel. The majority of the other assessors showed 
only limited deviation from the preset benchmark scores. After 
this structured assessment, all pathologists participated in face- 
to- face group meetings where discrepant cases of the assessment 
rounds were discussed. Although we speculate that these assess-
ments and group discussions will likely have improved their 
assessments and homogeneity, no formal evaluation has been 
performed on their performance.
Meanwhile, the national review panel has become operational. 
This platform is driven by reviews of the eight core pathologists 
and concentrates on revisions for alleged LGD and indefinite for 
dysplasia (IND) from centres throughout the Netherlands.
The aim of this study was to evaluate the performance of all 
pathologists of the eight BO expert centres in the assessment of 
the first 80 prospective LGD reviews submitted to the Dutch 
Barrett’s Pathology Review panel and to assess if the ‘non- core’ 
pathologists were homogeneous in their assessments with the 
eight core pathologists.
MeThOds
Case submission and scanning
Eighty BO surveillance cases with a diagnosis of IND or LGD 
during surveillance endoscopy were submitted to the Dutch 
Barrett’s Pathology Review panel (table 1).
Requests for consultation were submitted by gastroenterolo-
gists or pathologists via a dedicated website ( www. barrett. nl), 
on which pathology slides were requested by the back office of 
the review panel. All slides were digitalised, using a scanner with 
a ×20 microscope objective (Slide, Olympus, Tokyo, Japan). 
Digitalised slides were checked for focus and acuity by the 
study coordinator, rescanned if necessary and stored on a secure 
server. Subsequently pathologists were invited by email to review 
the slides.
histological assessment
All 15 pathologists independently assessed the digital cases 
through a virtual slide system (Digital Slidebox 4.5, Leica 
Microsystems, Dublin, Ireland) allowing them to assess the slides 
similarly to their conventional microscopic diagnostic practice. 
Cases were scored according to the modified Vienna criteria for 
GI neoplasms.13 Diagnostic categories were: NDBO, LGD, high- 
grade dysplasia (HGD) or more, or IND.
The five initial core expert BO pathologists individually 
assessed all cases at an earlier stage. Group meetings were 
organised to discuss all cases in which their individual scores 
did not show a 4/5 or 5/5 agreement. As such a consensus diag-
nosis was generated as a reference for all pathologists’ individual 
assessments.
All pathologists assessed the first 41 cases in phase I, after 
which a group discussion was held to discuss discrepant cases. 
Cases were considered discrepant if three or more pathologists 
disagreed with the consensus diagnosis. The group discussion 
consisted of two sessions with one teleconference and one face- 
to- face meeting. The cases were shown on screen and discussed 
plenary. A total of nine cases was discussed. Pathologists had 
access to their own score and the consensus diagnosis after the 
group discussion but were unaware about their relative scores. 
After the group discussion, pathologists individually assessed 
another 39 cases in the phase II.
Quality criteria
As described in our previous study,12 we used the following 
outcome parameters to quantify the quality of the individual 
histological assessment of each pathologist:
1. Percentage of diagnosis of IND per pathologist.
2. Percentage agreement with the consensus diagnosis per pa-
thologist, using three diagnostic categories (NDBO, IND and 
LGD+HGD).
3. Percentage of cases with a consensus diagnosis of LGD or 
HGD underdiagnosed as NDBO per pathologist.
For these three quality criteria, we created benchmark scores 
based on the individual scores of the initial five core pathologists 
supplemented by the individual scores of the three pathologists 
who qualified as a core member based on their scores in the 
aforementioned study in which digitalised slides of 60 surveil-
lance endoscopies were assessed.12
Benchmark ranges for each of the three criteria were based on 
a 95% prediction interval (PI) of the individual scores of these 
eight core pathologists. The 95% PI was calculated as the mean 
score from the eight pathologists ±2.365 times the SD (based 
on a t- distribution with 7 df, since n=8 pathologists). The upper 
or lower limit of these ranges, depending on the criterion, were 
used as benchmark values. Pathologists who met the benchmark 
score for all three quality criteria during phase I were added to 
the core, and benchmark scores for phase II were calculated 
based on the new extended core panel.
Anonymised materials were used in this study, hereby waiving 
the need for ethical approval by the medical ethical committee of 
the Amsterdam UMC or obtaining informed consent.
The statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS V.24.0).
resulTs
baseline characteristics of samples in case sets
Baseline characteristics of patients, endoscopic findings, number 
of biopsies obtained and original histological diagnoses of phase 
I and phase II were similar and are shown in table 1.
Performance of pathologists in phase I
For the percentage of IND cases, six of seven aspirant panel 
members met the benchmark value of 28% with percentages 
ranging from 7.3% to 14.6%. Only one pathologist did not meet 
the required performance score and diagnosed 31.7% of cases as 
IND (table 2).
For the percentage agreement with the consensus diagnosis, 
one pathologist met the benchmark lower limit of 69%, while 
three others just fell outside the range with a score of 68.3%.
The benchmark value for the percentage of consensus LGD 
and HGD cases underdiagnosed as NDBO was 11%, and six 
pathologists fell within this value. One pathologist clearly did 
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and hGd cases 
underdiagnosed as 
ndbO (n (%)) n=28
Core pathologists
  1 24.4 82.9 0
  2 9.8 80.5 2 (7.1)
  3 22.0 80.5 1 (3.6)
  4 7.3 87.8 1 (3.6)
  5 9.8 78.0 3 (10.7)
New core pathologists
  B 12.2 78.0 1 (3.6)
  E 12.2 75.6 1 (3.6)
  J 17.1 73.2 1 (3.6)
Aspirant panel members
  A 12.2 39.0 16 (57.0)
  C 14.6 58.5 1 (3.6)
  D 31.7 65.9 2 (7.1)
  F 12.2 70.7 0
  G 12.2 68.3 2 (7.1)
  H 7.3 68.3 1 (3.6)
  I 9.8 68.3 1 (3.6)
Benchmark value† ≤28 ≥69 ≤3 (11)
red, score does not fall within benchmark values
green, score falls within benchmark values
*NDBO/IND/LGD+HGD.
†Based on eight core pathologists.
HGD, high- grade dysplasia; IND, indefinite for dysplasia; LGD, low- grade dysplasia; 
NDBO, non- dysplastic Barrett’s oesophagus.









and hGd cases 
underdiagnosed 
as ndbO (n (%)) 
n=23
Core pathologists
1 17.9 89.7 0
2 10.3 87.2 2 (8.7)
3 28.2 71.8 2 (8.7)
4 20.5 87.2 2 (8.7)
5 17.9 82.1 0
New core pathologists
B 7.7 74.4 2 (8.7)
E 25.6 69.2 1 (4.3)
J 12.8 71.8 1 (4.3)
New core pathologist after phase 1
F 33.3 61.5 1 (4.3)
Aspirant panel members
A 2.6 56.4 7 (30.4)
C 7.7 66.7 0
D 12.8 64.1 0
G 12.8 66.7 2 (8.7)
H 12.8 69.2 1 (4.3)
I 15.4 76.9 1 (4.3)
Benchmarkvalue† ≤38 ≥56 ≤3 (13)
red, score does not fall within benchmark values
green, score falls within benchmark values
*NDBO/IND/LGD+HGD.
†Based on nine core pathologists.
HGD, high- grade dysplasia; IND, indefinite for dysplasia; LGD, low- grade dysplasia; 
NDBO, non- dysplastic Barrett’s oesophagus.
not qualify for this criterion, underdiagnosing 16 of the 28 
(57%) dysplasia cases as NDBO.
If all three quality criteria were taken into account, one 
pathologist met all benchmark scores and thus qualified as a 
core panel member. This pathologist was added to the core and 
incorporated in the benchmark ranges calculated for phase II. 
Four pathologists qualified for two criteria but showed a small 
deviation from the benchmark score for the percentage agree-
ment with the consensus diagnosis. Two pathologists did not 
meet the required benchmark scores for two of the three quality 
criteria.
Performance of pathologists in phase II
After the group discussion to discuss discrepant cases assessed in 
phase I and, subsequently, completing assessment of the next 39 
cases, all pathologists fell within the benchmark score of ≤38% 
for the percentage of IND cases in phase II; scores ranged from 
2.6% to 15.4% (table 3).
All six remaining aspirant members fell within the benchmark 
range for percentage agreement with the consensus diagnosis.
Five of the six pathologists met the benchmark value for 
percentage of cases with a consensus diagnosis of LGD or HGD 
underdiagnosed as NDBO (table 3). They had zero (n=2), one 
(n=2) or two (n=1) underdiagnosed cases (median percentage 
4.3% vs 4.3% for core pathologists).
One pathologist persisted in underdiagnosing a significant 
number of dysplastic cases as NDBO (7/23: 30.4%).
At the end of phase II, five of the six remaining aspirant panel 
members met all quality criteria.
dIsCussIOn
The aim of this study was to evaluate the performance of the 
GI pathologists of the eight BO expert centres in the assess-
ment of the first 80 consecutive review cases submitted to the 
Dutch Barrett’s Pathology Review panel with an initial diag-
nosis of IND or LGD. In our ambition to expand the current 
panel of eight core pathologists, while maintaining assessment 
quality and homogeneity, benchmark quality criteria based on 
the results of the core pathologists were used. These criteria 
enabled us to assess the ongoing process of homogenising future 
panel members. Assessments were done in two phases, with a 
group discussion to discuss discrepancies after phase I in order 
to further homogenise assessments.
When comparing the performance scores of the seven non- 
core pathologists to the benchmark scores, one out of seven aspi-
rant panel members met all three benchmark quality criteria in 
phase I and was added to the core. Five out of the remaining six 
pathologists did not meet the benchmark value for only one of 
the three performance scores, percentage agreement, with three 
pathologists scoring only marginally below the required bench-
mark value (68.3% vs 69%). After the group discussion, five 
of the six remaining non- core pathologists met the benchmark 
values for all quality criteria during phase II.
This study is the third in a series of studies with this group of 
pathologists and includes the third independent set of histology 
cases. As with the previous studies, individual assessments were 
complemented with face- to- face group discussions, discussing 
discrepant cases from the slide set.9–12 The current study demon-
strates that 14 pathologists can be considered homogenous in 
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their assessments, which implies that these 14 pathologists 
are interchangeable as panel members of the Dutch Barrett’s 
Pathology Review panel.
In contrast to our earlier studies, we did not assess intraob-
server agreement since the assessors only assessed all cases once. 
We decided not to use this variable as a benchmark quality crite-
rion. Since kappa resembles the agreement percentage corrected 
for chance, kappa is influenced by the prevalence of the diag-
nosis and thus the variance over the different categories. Since 
the cases submitted for review by Dutch Barrett’s Pathology 
Review panel mainly consisted of dysplastic cases the variance 
is low, leading to a high agreement by chance. This results in 
low kappas and is therefore not a reliable representation of the 
quality of the assessments.
Strengths of this study are the use of a digitalised case set of 
consecutive BO cases with IND/LGD submitted for review from 
all over the Netherlands. Therefore, this case selection reflects 
the daily workload of the Dutch Barrett’s Pathology Review 
panel. This study builds on three earlier studies in which pathol-
ogists were trained through structured assessments and group 
discussions. All pathologists participating in this study come 
from the eight Barrett Expert Centers in the Netherlands and 
thus represent the full potential for histological reviews of the 
Dutch Barrett’s Pathology Review panel.
A limitation is that slides come from different laboratories 
around the Netherlands. This may have affected slide inter-
pretability, especially for pathologists that are relatively new to 
reviewing cases from outside their own centre. However, this 
reflects the reality of our review panel, which per definition will 
receive consultations from different pathology laboratories.
Another point worth mentioning is that we used the consensus 
diagnosis made by our five core pathologists as training refer-
ence for the other pathologists. This means that our approach 
aimed to homogenise the assessments of the panel’s members. 
Our study set lacked follow- up information of the cases used 
and therefore we cannot prove that this homogenisation indeed 
improves outcomes. The consensus gold standard diagnosis in 
this study is based on five core pathologists who have extensive 
experience and an international reputation in the field of BO 
and have collaborated intensively in the Dutch Barrett advi-
sory committee over the course of many years.9 14 15 Moreover, 
their assessments have been validated by comparing their diag-
nosis to the histological outcome during follow- up in multiple 
studies, demonstrating their diagnoses to be predictive of 
progression risk.1–3 Based on aforementioned data, we assume 
that the consensus diagnosis of our five core pathologists is a 
justified reference for the remaining panellists and that homo-
genising our panel based on this reference will likely improve 
outcomes.
In the future, several important steps will be taken while the 
Dutch Barrett’s Pathology Review panel proceeds.
A prediction model will be set up to establish how many 
pathologist’s assessments are needed in order to obtain a reliable 
diagnosis. The algorithm will incorporate the performance score 
of the pathologist in previous assessments with the outcome 
of his or her review to decide how many additional patholo-
gists will have to review that specific case in order to retrieve 
a consensus diagnosis with the same reliability as used in the 
current study. This will enable an efficient and equal distribution 
of the workload.
Online group discussions will be continued to discuss cases 
without a majority diagnosis. In addition, annual trainings will 
be held, and assessment of homogeneity of all panel members 
will be renewed periodically.
This slide set of the first 80 consecutive review cases will be 
used in an online training programme for other pathologists and 
pathology residents to improve the histopathological assessment 
of BO. This training module will be accredited and freely avail-
able. Information from all study sets and group discussions will 
be incorporated. Pathologists and residents with an interest in 
BO will be able to improve their skills and compare their perfor-
mance to our panel.
A lot of time and effort has been put in the training sets, assess-
ment of digital pathology, development of the quality criteria 
and the infrastructure of the platform. Other future panels can 
benefit from these steps we have taken. In systems where endo-
scopic surveillance for Barrett’s patients is performed, there 
should be enough financial ability to run an expert panel since 
the panel will recoup its costs. Expert pathology will signifi-
cantly improve the efficacy of Barrett surveillance by preventing 
unnecessary expensive endoscopies in patients with a low risk 
of progression and will also identify the subgroup with a truly 
increased risk of progression.
Take home messages
 ► Guidelines dictate expert review for a diagnosis of low- grade 
dysplasia in Barrett’s oesophagus (BO).
 ► A web- based digital expert review panel has been set up in 
the Netherlands.
 ► Pathologists from Dutch BO expert centres have participated 
in structured assessments and group discussions to 
homogenise assessments.
 ► This study shows that the expert review panel could be 
expanded to a total of 14 panel members while maintaining 
assessment quality and homogeneity by using predefined 
benchmark quality criteria for histological assessment of 
biopsies with low- grade dysplasia.
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